Haduvio (oral nalbuphine ER) — Interim data
Q4 2026
The protocol includes a sample size re-estimation (SSRE) analysis once 50% of the participants complete treatment which is expected to occur in the fourth quarter of 2026.Source filing
TRVI biotech catalysts & pipeline
TREVI THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
Haduvio (oral nalbuphine ER) — Topline data
H2 2027
The Company will report the outcome of the SSRE once available and expects to report topline results from the trial in the second half of 2027.Source filing
Haduvio (oral nalbuphine ER) — Topline data
H1 2028
Topline data from the 52-week fixed dosing OCEAN-1 trial is expected in the first half of 2028.Source filing